BD CEO Details $1B Nebraska Expansion, Plans to Make All U.S. Needles Domestically
BDX sits 42% above its 52-week low of $127.536 on light trading volume (0.4× avg).
Summary
CEO Tom Polen's interview adds concrete operational details to BD's $19B U.S. manufacturing expansion announced yesterday. The company will invest over $1B in Nebraska alone, eventually produce all U.S. needles domestically using American-made steel, and add five billion medical consumables annually. Raymond James estimates BD paid about $290M in tariffs last fiscal year—an 85 cent EPS drag—and says the deal could eliminate the vast majority of U.S. tariffs. This is the first medtech onshoring agreement with the government, following similar deals in pharma and tech. The specifics on Nebraska and needle production give investors a clearer picture of the multiyear capital commitment and tariff relief magnitude.
At the time of this announcement, BDX was trading at $181.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $49.4B. The 52-week trading range was $127.54 to $193.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.